← board
BGMS
distress 8/10 · high distress / dilution risk$0.87-4%today-95% from 52w high
Revenue
pre-revenue
Liquidity
$3M
Runway
0.5 yrs
Shares 1y
+147%
Price & events
-37.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.8%
1D
-8.9%
1W
+29.2%
1M
-8.9%
3M
-34.4%
6M
-93.8%
1Y
-99.5%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $4.78M
- Volume
- 13.46K
- 52 Week Range
- $0.60 – $17.15
- Total Shares
- 5.52M
- Float Shares
- 3.46M
- Short %
- 2.43%
- % Held by Insiders
- 45.20%
- % Held by Institutions
- 1.79%
- RVOL
- 0.09x
- Beta
- -0.37
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025-07-07partnershipAmendment to exchange agreement with Fitters Parent for share exchange transactionSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 5,519,456 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.